skip to Main Content

IRBM CSO Carlo Toniatti on the Evolving CRO Role in Drug Development, Emerging Approaches in Oncology & the Potential of AI

Carlo Toniatti, chief scientific officer of IRBM

Carlo Toniatti, chief scientific officer of IRBM, gives his insights into how the increased participation of early-stage ventures in the drug R&D process and the plethora of new research approaches that are recalibrating the role of CROs such as IRBM. An experienced oncologist, Toniatti also weighs in on the key emerging trends within the cancer field and assesses AI’s potential as a truly transformative asset within the drug developer’s toolbox.

Article published on Pharma Boardroom – 07/10/2021

Read the original article on Pharma Boardroom

Back To Top